Laboratoire français du Fractionnement et des Biotechnologies Sustainability Profile
Laboratoire français du Fractionnement et des Biotechnologies (LFB) is a leading biopharmaceutical company headquartered in France, with significant operations across Europe and North America. Founded in 1994, LFB has established itself as a key player in the biopharmaceutical industry, specialising in the development and production of innovative therapies derived from human plasma. LFB's core offerings include a range of plasma-derived medicinal products, particularly in the fields of immunology, haematology, and critical care. What sets LFB apart is its commitment to high-quality standards and advanced biotechnological processes, ensuring the safety and efficacy of its products. With a strong market position, LFB has achieved notable milestones, including the expansion of its product portfolio and global reach, solidifying its reputation as a trusted provider in the biopharmaceutical sector.
DitchCarbon Score
How does Laboratoire français du Fractionnement et des Biotechnologies's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Laboratoire français du Fractionnement et des Biotechnologies's score of 11 is lower than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Laboratoire français du Fractionnement et des Biotechnologies's reported carbon emissions
Laboratoire français du Fractionnement et des Biotechnologies currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the organisation. As a result, the company appears to lack formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. This absence of data may reflect a broader industry context where many organisations are still developing their sustainability strategies. Without specific emissions data or reduction initiatives, it is challenging to assess the company's environmental impact or commitment to climate action.
How Carbon Intensive is Laboratoire français du Fractionnement et des Biotechnologies's Industry?
How Carbon Intensive is Laboratoire français du Fractionnement et des Biotechnologies's Location?
Laboratoire français du Fractionnement et des Biotechnologies's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Laboratoire français du Fractionnement et des Biotechnologies has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
